Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration. Mugavero MJ, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e. J Acquir Immune Defic Syndr. 2011. PMID: 21857357 Free PMC article. Clinical Trial.
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Knobel H, Miró JM, Mahillo B, Domingo P, Rivero A, Ribera E, Gonzalez J, Sanz J, González A, Blanco JL, Boix V, Force L, Llibre JM, Dalmau D, Arroyo JA, De la Torre J, Rodriguez D, Montes ML, Arranz A, Sarasa M; Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Knobel H, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1276-81. doi: 10.1097/01.qai.0000137372.18814.34. J Acquir Immune Defic Syndr. 2004. PMID: 15385735 Clinical Trial.
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Ribera E, Azuaje C, Lopez RM, Domingo P, Soriano A, Pou L, Sánchez P, Mallolas J, Sambea MA, Falco V, Ocaña I, Lopez-Colomes JL, Gatell JM, Pahissa A. Ribera E, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-23. doi: 10.1097/01.qai.0000182629.74336.4d. J Acquir Immune Defic Syndr. 2005. PMID: 16249706 Clinical Trial.
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
Lamarca A, Clumeck N, Plettenberg A, Domingo P, Fu K, Craig C, Zhao H, Watson M, Gordon D, Scott T. Lamarca A, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):598-606. doi: 10.1097/01.qai.0000214821.33905.5c. J Acquir Immune Defic Syndr. 2006. PMID: 16652033 Clinical Trial.
Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.
Moreno S, Domingo P, Palacios R, Santos J, Falcó V, Murillas J, Estrada V, Ena J, Alvarez ML; Recover Study Group. Moreno S, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2006 Jul;42(3):385-7. doi: 10.1097/01.qai.0000221690.54349.83. J Acquir Immune Defic Syndr. 2006. PMID: 16763528 No abstract available.
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.
Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM. Falcó V, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31. doi: 10.1097/QAI.0b013e31817bec64. J Acquir Immune Defic Syndr. 2008. PMID: 18667930
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.
Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group. Arribas JR, et al. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5. J Acquir Immune Defic Syndr. 2009. PMID: 19349870 Clinical Trial.
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. Among authors: domingo p. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
758 results